What is the first-line medication to add for a 48-year-old female with moderate generalized anxiety disorder and depression, chronic migraine, and fibromyalgia who is already taking duloxetine (SNRI) 60 mg daily and gabapentin 300 mg nightly?

First-Line Medication Recommendation

Add bupropion XL 150 mg daily (titrate to 300 mg daily as tolerated) as augmentation to the current duloxetine regimen.

Rationale for Bupropion as First-Line Addition

Given this patient's clinical profile—moderate depression with prominent fatigue, low motivation, cognitive impairment, and anxiety in the context of chronic migraine and fibromyalgia—bupropion represents the optimal augmentation strategy for several key reasons:

Why Bupropion Over Other Options

Non-serotonergic mechanism is critical here. The patient is already on duloxetine 60 mg daily (an SNRI), which provides serotonergic and noradrenergic coverage. Adding another serotonergic agent (SSRI or higher-dose SNRI) would increase the risk of serotonergic adverse effects, including potential worsening of migraine sensitivity, without addressing the specific symptom gaps 1.

Target symptom profile strongly favors bupropion:

• Energy and motivation deficits: Bupropion's dopaminergic and noradrenergic effects directly target the fatigue, low motivation, and anhedonia that persist despite duloxetine
• Cognitive functioning: The patient's migraine-related cognitive impairment (concentration, processing speed, word-finding) may benefit from bupropion's pro-cognitive effects through dopaminergic enhancement
• Anxiety management: While bupropion is not traditionally anxiolytic, the patient's anxiety appears largely reactive to cognitive impairment and occupational concerns rather than primary generalized anxiety—addressing the underlying depression and cognitive symptoms may reduce anticipatory anxiety

Duloxetine Continuation is Appropriate

Duloxetine 60 mg daily should be continued as it provides meaningful benefit for fibromyalgia 2, 3, 1. The evidence strongly supports duloxetine for fibromyalgia pain management, with 60 mg daily being the optimal dose—higher doses do not confer additional benefit and increase adverse effects 1. Duloxetine also has moderate-certainty evidence for generalized anxiety disorder 4 and provides partial coverage for her mood symptoms.

Alternative Considerations and Why They Are Second-Line

Pregabalin is a reasonable alternative but is second-line in this case:

• Strong evidence for fibromyalgia pain 2, 3, 5 and generalized anxiety disorder 6, 7
• However, the patient is already on gabapentin 300 mg nightly (same mechanism of action via calcium channel α2δ ligands 8)
• Pregabalin's sedating effects 8 may worsen her existing fatigue and cognitive symptoms
• Does not address the core depressive symptoms of low motivation and energy
• Consider pregabalin if anxiety remains prominent after addressing depression, or if combination therapy is needed (evidence supports duloxetine + pregabalin combination for fibromyalgia 5)

Increasing duloxetine dose to 120 mg daily is not recommended:

• FDA labeling explicitly states "no evidence that doses greater than 60 mg/day confer additional benefit" for fibromyalgia and generalized anxiety disorder 1
• Higher doses associated with increased adverse effects without additional efficacy 1

SSRIs are not appropriate as augmentation:

• Would add serotonergic burden without addressing non-serotonergic symptom domains
• No advantage over current SNRI therapy for this symptom profile

Migraine Considerations and Coordination

Critical caveat: Bupropion can lower seizure threshold and there are theoretical concerns about migraine exacerbation in some patients. Coordination with neurology prior to initiation is essential as noted in the clinical impression. However, bupropion is not contraindicated in migraine and may be beneficial for comorbid depression 9.

Migraine prophylaxis optimization should occur concurrently:

• The patient's severe, chronic migraine is a major contributor to her overall symptom burden
• Evidence supports topiramate 10, propranolol 10, or CGRP antagonists 10 for migraine prevention
• Some migraine prophylaxis agents (e.g., topiramate, valproate) have mood-stabilizing properties that could provide additional psychiatric benefit 9

Practical Implementation

Starting regimen:

• Bupropion XL 150 mg once daily in the morning
• Continue duloxetine 60 mg daily
• Continue gabapentin 300 mg nightly

Titration:

• After 1 week, increase bupropion XL to 300 mg daily if tolerated
• Monitor for activation, anxiety, insomnia, and any change in migraine frequency
• Allow 4-6 weeks at target dose to assess full therapeutic response

Monitoring:

• Weekly check-ins for first month to assess tolerability
• Specific attention to anxiety levels, sleep, and migraine frequency
• If anxiety worsens significantly, consider adding buspirone or switching strategy

If Bupropion Fails or Is Not Tolerated

Next steps would be:

1. Pregabalin augmentation (150-300 mg/day) for anxiety and fibromyalgia, accepting potential sedation 2, 3, 5, 6
2. Mirtazapine (15-30 mg at bedtime) for depression, anxiety, and sleep—though weight gain and sedation are concerns 11
3. Quetiapine low-dose (25-150 mg) for anxiety augmentation, though metabolic effects and sedation limit use 7, 12

Common Pitfalls to Avoid

• Do not add an SSRI to duloxetine—excessive serotonergic burden without addressing symptom gaps
• Do not increase duloxetine above 60 mg—no additional benefit per FDA labeling 1
• Do not discontinue duloxetine—it is providing meaningful fibromyalgia benefit
• Do not ignore the migraine burden—psychiatric symptoms will not fully resolve without better migraine control
• Do not overlook perimenopausal factors—hormonal evaluation and potential HRT may significantly impact mood, anxiety, and migraine 13